Washington Capital Management Inc. Takes $226,000 Position in Penumbra, Inc. (NYSE:PEN)

Washington Capital Management Inc. acquired a new position in Penumbra, Inc. (NYSE:PEN - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 950 shares of the company's stock, valued at approximately $226,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Janus Henderson Group PLC boosted its stake in shares of Penumbra by 128.1% during the third quarter. Janus Henderson Group PLC now owns 668,873 shares of the company's stock valued at $129,967,000 after purchasing an additional 375,684 shares in the last quarter. Thrivent Financial for Lutherans boosted its position in Penumbra by 3,832.3% during the 3rd quarter. Thrivent Financial for Lutherans now owns 368,298 shares of the company's stock valued at $71,564,000 after acquiring an additional 358,932 shares in the last quarter. Champlain Investment Partners LLC increased its holdings in shares of Penumbra by 20.6% in the 3rd quarter. Champlain Investment Partners LLC now owns 1,547,972 shares of the company's stock valued at $300,786,000 after acquiring an additional 264,122 shares during the period. Massachusetts Financial Services Co. MA purchased a new stake in shares of Penumbra during the third quarter valued at about $31,965,000. Finally, Braidwell LP grew its holdings in Penumbra by 70.0% in the third quarter. Braidwell LP now owns 361,428 shares of the company's stock worth $70,229,000 after purchasing an additional 148,834 shares during the last quarter. 88.88% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Penumbra

In other Penumbra news, EVP Johanna Roberts sold 600 shares of the business's stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $239.74, for a total transaction of $143,844.00. Following the completion of the sale, the executive vice president now owns 64,044 shares of the company's stock, valued at approximately $15,353,908.56. The trade was a 0.93 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Harpreet Grewal sold 167 shares of Penumbra stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $241.28, for a total transaction of $40,293.76. Following the sale, the director now directly owns 8,530 shares in the company, valued at $2,058,118.40. This trade represents a 1.92 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 33,819 shares of company stock valued at $8,129,483. 5.00% of the stock is owned by corporate insiders.

Penumbra Stock Up 0.5 %

Shares of NYSE PEN traded up $1.38 during midday trading on Thursday, hitting $271.11. 102,003 shares of the company's stock were exchanged, compared to its average volume of 474,226. The company has a market cap of $10.41 billion, a PE ratio of 315.13, a P/E/G ratio of 2.02 and a beta of 0.52. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.82 and a quick ratio of 3.25. Penumbra, Inc. has a twelve month low of $148.00 and a twelve month high of $277.89. The firm's fifty day simple moving average is $249.88 and its 200-day simple moving average is $217.76.

Penumbra (NYSE:PEN - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $0.85 earnings per share for the quarter, topping analysts' consensus estimates of $0.69 by $0.16. Penumbra had a net margin of 2.97% and a return on equity of 8.99%. The firm had revenue of $301.04 million during the quarter, compared to analysts' expectations of $297.36 million. During the same quarter in the prior year, the business earned $0.67 EPS. Penumbra's quarterly revenue was up 11.1% compared to the same quarter last year. Research analysts predict that Penumbra, Inc. will post 2.81 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Piper Sandler boosted their target price on shares of Penumbra from $235.00 to $250.00 and gave the company an "overweight" rating in a research report on Wednesday, November 20th. Truist Financial raised their price target on shares of Penumbra from $240.00 to $285.00 and gave the company a "buy" rating in a research report on Wednesday, December 18th. Citigroup raised their target price on Penumbra from $220.00 to $245.00 and gave the company a "neutral" rating in a research report on Wednesday, December 11th. BTIG Research upped their target price on Penumbra from $232.00 to $270.00 and gave the stock a "buy" rating in a research note on Tuesday, November 26th. Finally, Canaccord Genuity Group lifted their price target on shares of Penumbra from $260.00 to $323.00 and gave the company a "buy" rating in a research note on Monday, December 9th. Four equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $261.36.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.